{"id":141495,"title":"MedPal AI September Revenue Hits £3.2m as Annualised Run Rate Tops £38m","publisher":"Share Talk","author":"sharetalk","published":"2026-10-06T06:55:21+00:00","modified":"2026-10-06T07:07:07+00:00","canonical_url":"https://www.share-talk.com/medpal-ai-september-revenue-hits-3-2m-as-annualised-run-rate-tops-38m/","markdown_url":"https://www.share-talk.com/medpal-ai-september-revenue-hits-3-2m-as-annualised-run-rate-tops-38m.md","json_url":"https://www.share-talk.com/medpal-ai-september-revenue-hits-3-2m-as-annualised-run-rate-tops-38m.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["blood testing","eMARx","Jason Drummond","Juno","MedPal AI plc","MedPal Health OS","MPAL","NHS pharmacy services"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/10/062d5556-b52c-423d-b5c5-bbd7c3857405.png?fit=1727%2C911&ssl=1","format":"news","language":"en-GB","content":"[MedPal AI plc (AIM: MPAL; FRA: Z1N)](https://www.investegate.co.uk/announcement/rns/medpal-ai-plc--mpal/september-update-and-circular-to-shareholders/9807662) reported another sharp increase in trading during September, with Group revenue reaching **£3.2 million**.\n\nThat takes the Group’s annualised revenue run rate to more than **£38 million**, compared with more than **£35 million reported on 21 September** and £28 million based on August trading.\n\nImportantly, MedPal stressed that the £38 million figure is simply **September revenue multiplied by twelve and is not a forecast of future revenue**.\n\n**New Health led growth, generating more than £2.7 million in revenue from over 22,600 orders in September**.\n\nThat represents an increase of approximately **50% from £1.8 million in August**.\n\nTrading also accelerated materially towards the end of the month, with daily New Health revenue during the **final 11 days of September around 50% higher than during the first 19 days**.\n\nNew Health has now served more than **33,500 customers since marketing began in July 2026**, up from more than 25,000 customers reported on 21 September.\n\nA particularly important development for the economics of the business was the growing contribution from existing customers and recurring activity.\n\nMore than **£1 million of September Group revenue came from New Health repeat orders, NHS prescriptions and eMARx subscriptions**, representing around one-third of total Group revenue for the month.\n\nMedPal said New Health repeat orders incur **no customer acquisition cost** and produced an average order value approximately **20% higher than first orders**.\n\nThe Board expects the proportion of repeat and recurring revenue to increase as customers acquired during the rapid expansion since July reach their first reorder dates.\n\nAcross the Group, MedPal dispensed **58,859 prescription items and orders during September**.\n\nThe expanded **GLP-1 production line at Sarus Court remains scheduled to open by the end of October**, increasing capacity to as many as **14,000 orders per day**.\n\nThe expansion was funded from MedPal’s **£5 million placing completed on 24 September 2026**.\n\nManagement said its immediate priorities are expanding capacity, increasing the proportion of repeat business and completing the **working-capital facility discussions announced on 21 September**.\n\nThe company expects to provide its next trading update covering October in **early November 2026**.\n\nFor investors, September provides further evidence that MedPal’s customer-acquisition strategy is translating into rapid top-line growth, while the emerging repeat-order contribution could materially improve unit economics because those sales do not carry the same acquisition cost as first orders.\n\nThe major operational catalyst is the **Sarus Court expansion to 14,000 orders per day**, which should remove an important capacity constraint if demand continues growing at the current pace.\n\nHowever, investors should distinguish the current **£38 million-plus annualised run rate from a full-year forecast**, particularly given how recently New Health launched and the exceptionally rapid sequential growth being recorded.\n\nThe other key issue remains funding: despite September’s strong revenue growth and the recent £5 million placing, the company is still seeking to conclude **additional working-capital financing**.\n\nThe next important tests will therefore be **successful commissioning of the expanded GLP-1 line, continued growth in repeat orders, completion of the working-capital facility and October’s trading performance**.\n\n**Investor takeaway: ***MedPal AI generated approximately £3.2 million of Group revenue in September, lifting its annualised revenue run rate above £38 million. New Health revenue jumped around 50% month-on-month to more than £2.7 million, while repeat orders and recurring revenues exceeded £1 million. Growth is accelerating, but the £38 million figure is an annualised September run rate rather than a forecast, and discussions over an additional working-capital facility remain ongoing.*"}